← Back to home

TO EVALUATE THE EFFICACY OF FRUQUINTINIB AND PIRFENIDONE IN COMBINATION WITH ANTI-PD-1 ANTIBODY IN COLORECTAL CARCINOMA

Clinical trials for TO EVALUATE THE EFFICACY OF FRUQUINTINIB AND PIRFENIDONE IN COMBINATION WITH ANTI-PD-1 ANTIBODY IN COLORECTAL CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new TO EVALUATE THE EFFICACY OF FRUQUINTINIB AND PIRFENIDONE IN COMBINATION WITH ANTI-PD-1 ANTIBODY IN COLORECTAL CARCINOMA trials appear

Sign up with your email to follow new studies for TO EVALUATE THE EFFICACY OF FRUQUINTINIB AND PIRFENIDONE IN COMBINATION WITH ANTI-PD-1 ANTIBODY IN COLORECTAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Can a Three-Drug combo outsmart Hard-to-Treat colorectal cancer?

Disease control Recruiting now

This phase 2 trial is testing whether combining three drugs—fruquintinib, pirfenidone, and pembrolizumab—can help people with advanced or metastatic colorectal cancer that has not responded to standard treatments. The study includes 25 participants with a specific type of tumor (…

Matched conditions: TO EVALUATE THE EFFICACY OF FRUQUINTINIB AND PIRFENIDONE IN COMBINATION WITH ANTI-PD-1 ANTIBODY IN COLORECTAL CARCINOMA

Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control

Last updated Aug 19, 2026 09:00 UTC

TO EVALUATE THE EFFICACY OF FRUQUINTINIB AND PIRFENIDONE IN COMBINATION WITH ANTI-PD-1 ANTIBODY IN COLORECTAL CARCINOMA

Get alerted when new TO EVALUATE THE EFFICACY OF FRUQUINTINIB AND PIRFENIDONE IN COMBINATION WITH ANTI-PD-1 ANTIBODY IN COLORECTAL CARCINOMA trials appear

Can a Three-Drug combo outsmart Hard-to-Treat colorectal cancer?